The world's largest vaccine manufacturer by volume, Serum Institute of India, has sought permission from the Centre to supply 50 lakh doses of Oxford COVID-19 vaccine Covishield to the United Kingdom, citing an agreement with AstraZeneca in this regard.
It has, however, assured India that its own anti-coronavirus vaccination programme will not be disturbed because of this supply.
This development came amid reports that the UK's anti-coronavirus inoculation programme has been hit due to a delay in the supply of the second batch of vaccines.
In a communique to Union Health Secretary Rajesh Bhushan on Tuesday, the Director of Government and Regulatory Affairs at the Pune-based Serum Institute of India (SII), Prakash Kumar Singh, sought permission to supply 50 lakh doses of Covishield stating that India's anti-coronavirus vaccination programme will not be affected.
It referred to a license agreement between AstraZeneca UK Limited and the Serum Institute of India in June 2020 with relation to technology transfer from AZ for manufacture and supply of Covishield.
"Under this agreement, it was agreed that Serum Institute of India will supply any AstraZeneca country where AstraZeneca has commitments anywhere in the world. It was further agreed that, in return for getting access to the AZ technology AZD1222, Serum Institute Of India Pvt. Ltd will treat AstraZeneca as a priority customer, whether it is for drug substance or finished product," Singh stated.
According to the agreement, Serum Institute has to supply millions of doses of Covishield to AstraZeneca according to their requirement. "We have to supply at least 50 lakh doses to AstraZeneca immediately for use in the UK."
"This is of utmost priority as AstraZeneca has conveyed and is also reminding us of our obligation to supply Covishield to them according to the agreement. AstraZeneca and representative of the UK Government have also conveyed to us today morning that if these minimum 50 lakh doses are not supplied to the UK immediately this week then the UK government might have to halt the vaccination programme," Singh said.
The letter also reminded the government that the Serum Institute has received the technology to manufacture Covishield from AstraZeneca-Oxford and need to honour the commitment to supply at least 50 lakh doses of the vaccine.
"We are sure, considering the gravity of the situation and prestige of our company as well as our country is at stake, you will definitely intervene and give permission to us to supply at least 50 lakh doses of Covishield to the UK this week. We will be highly obliged for the same. We assure you that the Government of India's vaccination programme will not be disturbed because of this supply," Singh stated.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU